Vilazodone Hydrochloride Tablet, Film Coated
Product Images NDC 46708-234

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone Hydrochloride (NDC 46708-234). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vilazodone-10mg.jpg (Vilazodone 10mg)

Label for Vilazodone Hydrochloride Tablets 10 mg by Alembic Pharmaceuticals Limited. The oral film-coated tablet packaging shows NDC 46708-232-30 with 30 tablets per package. It includes storage instructions and a pharmacist medication guide notice, indicating prescription use only.*

FDA Label Image

Vilazodone-20mg.jpg (Vilazodone 20mg)

Label for Vilazodone Hydrochloride Tablets 20 mg, film-coated oral tablets supplied by Alembic Pharmaceuticals Limited. The package contains 30 tablets. Label includes storage instructions, pharmacist dispensing guidance, and the NDC code 46708-233-30 with barcode.*

FDA Label Image

Vilazodone-40mg.jpg (Vilazodone 40mg)

Label for Vilazodone Hydrochloride Tablets 40 mg, 30 count, film-coated oral tablets. The label includes storage instructions, manufacturer details (Alembic Pharmaceuticals Limited), and a barcode. The product is prescription-only (Rx only) and dispensed with a medication guide.*

FDA Label Image

Vilazodone-fig.jpg (Vilazodone Fig)

Chemical structure of Vilazodone Hydrochloride, showing its molecular components including a cyano-substituted indole, piperazine, and a benzofuran carboxamide moiety with an associated hydrochloride group.*

FDA Label Image

Figure 3 (Vilazodone Fig3)

A chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC relative to reference groups. The graph compares effects of age (>65 years), gender (females), and varying degrees of renal and hepatic impairment (mild, moderate, severe) on these pharmacokinetic measures, with change relative to reference values on the x-axis.*

FDA Label Image

Figure 2 (Vilazodone Figr2)

A chart titled 'Impact of Vilazodone on Other Drug Pharmacokinetics' showing fold changes and 90% confidence intervals for multiple drug substrates affected by vilazodone. The substrates include CYP3A4, CYP1A2, CYP2A6, CYP2A9, CYP2A19, and P-gp substrates such as nifedipine, caffeine, debrisoquine, flurbiprofen, mephenytoin, and digoxin, plotted against a reference change of 1. The chart compares pharmacokinetic parameters such as AUCp, CRmp, URmp, CLrm, Um, Cmax, and AUC to illustrate vilazodone's impact on these drugs' pharmacokinetics.*

FDA Label Image

Vilazodone-figur1.jpg (Vilazodone Figur1)

A forest plot titled 'Effect of Other Drugs on Vilazodone Pharmacokinetics' showing fold change and 90% confidence intervals for Cmax and AUC following co-administration with ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole), with changes plotted relative to a reference value of 1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.